Eltrombopag in patients with chronic liver disease
Eltrombopag in patients with chronic liver disease
复制标题
艾曲波帕在慢性肝病患者中的应用
DOI：
--
复制
发表时间：
2013
影响因子：
3.2
通讯作者：
N. Afdhal
中科院分区：
文献类型：
--
作者：
E. Giannini;N. Afdhal
前言：对于接受侵入性手术的慢性肝病患者或需要接受干扰素抗病毒治疗的患者，血小板减少症可能是最佳治疗的障碍。ELTROMBOPG是一种促血小板药物，作用于结合的血小板生成素受体，刺激巨核细胞生成和血小板生成。涉及的领域：本文总结了临床前研究和在慢性肝病患者中进行的研究。数据是基于PubMed对截至2012年11月发表的文献的搜索发现的期刊文章和国际会议的摘要。专家观点：eltrombopg已被证明能够减少接受侵入性手术的晚期肝病患者对血小板减少的需要，并有助于提高因血小板减少而不适合治疗的慢性丙型肝炎患者对基于干扰素的抗病毒治疗的持续病毒学应答率。在慢性肝病患者中，由于可能担心血栓栓子事件的发生和慢性肝病失代偿的可能性，应该准确地权衡给药的可能益处和药物的不良事件概况。
Introduction: Thrombocytopenia may represent a barrier to optimal management of chronic liver disease patients undergoing invasive procedures, or who need to be treated with interferon-based antiviral therapy. Eltrombopag is a thrombopoietic drug that acts upon binding thrombopoietin receptor and stimulates megakaryocytopoiesis and platelet production. Areas covered: A summary of the preclinical studies and of studies carried out in patients with chronic liver disease with eltrombopag are presented in this paper. Data are based on abstracts from journal articles and international conferences found in a PubMed search of literature published up to November 2012. Expert opinion: Eltrombopag has shown to be capable of reducing the need for platelet transfusion in thrombocytopenic patients with advanced liver disease undergoing invasive procedures and help increase the sustained virological response rate to interferon-based antiviral therapy in patients with chronic hepatitis C who were poor candidates to treatment because of thrombocytopenia. In chronic liver disease patients, the possible benefits of eltrombopag administration should be accurately weighed against the adverse events profile of the drug due to possible concerns regarding the occurrence of thromboembolic events and the potential for decompensation of chronic liver disease.
DOI：
10.1016/j.cgh.2009.02.021
发表时间：
2009-06
期刊：
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
影响因子：
--
作者：
Qamar AA;Grace ND;Groszmann RJ;Garcia-Tsao G;Bosch J;Burroughs AK;Ripoll C;Maurer R;Planas R;Escorsell A;Garcia-Pagan JC;Patch D;Matloff DS;Makuch R;Rendon G;Portal Hypertension Collaborative Group
通讯作者：
Portal Hypertension Collaborative Group